Eine Phase-III-Studie von HMPL-760 in Kombination mit R-GemOx versus Placebo in Kombination mit R-GemOx bei rezidiviertem/refraktärem DLBCL
Eine Phase-III-randomisierte, doppelblinde, positiv kontrollierte Studie zur Bewertung der Wirksamkeit, Sicherheit und Pharmakokinetik von HMPL-760 in Kombination mit R-GemOx im Vergleich zu Placebo in Kombination mit R-GemOx bei Patienten mit rezidiviertem/refraktärem diffus großzelligen B-Zell-Lymphom (DLBCL)
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.
The target population of this study includes patients with DLBCL who are relapsed or refractory.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Dongmei Chen, CPL
- Telefonnummer: 86-21-20671794
- E-Mail: dongmeic@hutch-med.com
Studienorte
-
-
-
Baoding, China
- Rekrutierung
- Baoding NO.1 Central Hospital
-
Kontakt:
- Haiying Yao
- Telefonnummer: 18617789030
- E-Mail: haiyingyaobd@163.com
-
Hauptermittler:
- Haiying Yao
-
Beijing, China
- Rekrutierung
- Beijing GoBroad Hospital
-
Hauptermittler:
- Kai Hu
-
Kontakt:
- Kai Hu
- Telefonnummer: 15010390336
- E-Mail: HK13610956245@163.com
-
Beijing, China
- Rekrutierung
- BEIJING TONGREN HOSPITAL, Capital Medical University
-
Hauptermittler:
- Liang Wang
-
Kontakt:
- Liang Wang
- Telefonnummer: 15001108693
- E-Mail: wangliangtrhos@126.com
-
Bengbu, China
- Rekrutierung
- The First Affiliated Hospital of Bengbu Medical College
-
Kontakt:
- Yanli Yang
- Telefonnummer: 13855249678
- E-Mail: Yangyanli0702@126.com
-
Hauptermittler:
- Yanli Yang
-
Changchun, China
- Rekrutierung
- The First Hospital of Jilin University
-
Hauptermittler:
- Ou Bai
-
Kontakt:
- Ou Bai
- Telefonnummer: 13039046656
- E-Mail: lbl2054@163.com
-
Changsha, China
- Rekrutierung
- Hunan Cancer Hospital
-
Hauptermittler:
- Hui Zhou
-
Kontakt:
- Hui Zhou
- Telefonnummer: 13975879796
- E-Mail: zhouhui9403@126.com
-
Changsha, China
- Rekrutierung
- The Second Xiangya Hospital of Central South University
-
Hauptermittler:
- Hongling Peng
-
Kontakt:
- Hongling Peng
- Telefonnummer: 18900766137
- E-Mail: Penghongling@aliyun.com
-
Changsha, China
- Rekrutierung
- People's Hospital of Hunan Province
-
Kontakt:
- Can Liu
- Telefonnummer: 137 8728 5260
- E-Mail: 617170469@qq.com
-
Hauptermittler:
- Can Liu
-
Chengdu, China
- Rekrutierung
- West China Hospital of Sichuan University
-
Hauptermittler:
- Liqun Zou
-
Kontakt:
- Liqun Zou
- Telefonnummer: 18980601027
- E-Mail: Clinical_Zou@163.com
-
Chengdu, China
- Rekrutierung
- Sichuan Provincial People's Hospital
-
Kontakt:
- Xiaobing Huang
- Telefonnummer: 18981838236
- E-Mail: hxb_trial@163.com
-
Hauptermittler:
- Xiaobing Huang
-
Chongqing, China
- Rekrutierung
- The First Affiliated Hospital of Chongqing Medical University
-
Hauptermittler:
- Xin Wang
-
Kontakt:
- Xin Wang
- E-Mail: 925170788@qq.com
-
Chongqing, China
- Rekrutierung
- Chongqing University Cancer Hospital
-
Hauptermittler:
- Yao Liu
-
Kontakt:
- Yao Liu
- E-Mail: liuyao101709@163.com
-
Fujian, China
- Rekrutierung
- Quanzhou First Hospital.Fujian
-
Kontakt:
- Xiongpeng Zhu
- Telefonnummer: 13805998581
- E-Mail: xiongpengzhu@163.com
-
Hauptermittler:
- Xiongpeng Zhu
-
Fuzhou, China
- Rekrutierung
- Fujian Medical University Union Hospital
-
Hauptermittler:
- Jianzhen Shen
-
Kontakt:
- Jianzhen Shen
- Telefonnummer: 138 0955 2722
- E-Mail: doctorsjz@163.com
-
Guangzhou, China
- Rekrutierung
- Sun Yat-sen University Cancer Center
-
Hauptermittler:
- Zhiming Li
-
Kontakt:
- Zhiming Li
- Telefonnummer: 13719189172
- E-Mail: lzmsysu@163.com
-
Guangzhou, China
- Rekrutierung
- Guangdong Provincial People's Hospital
-
Kontakt:
- Xiaojuan Wei
- Telefonnummer: 86 13560097145
- E-Mail: jxw919@hotmail.com
-
Hauptermittler:
- Xiaojuan Wei
-
Guangzhou, China
- Rekrutierung
- ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
-
Hauptermittler:
- Yuhua Li
-
Kontakt:
- Yuhua Li
- Telefonnummer: 13533706656
- E-Mail: liyuhua2011gz@163.com
-
Guiyang, China
- Rekrutierung
- The Affiliated Hospital of Guizhou Medical University
-
Hauptermittler:
- Yan Zhang
-
Kontakt:
- Yan Zhang
- Telefonnummer: 86 18984155172
- E-Mail: Zhangyan20010802@sina.com
-
Hangzhou, China
- Rekrutierung
- Zhejiang Cancer Hospital
-
Hauptermittler:
- Haiyan Yang
-
Kontakt:
- Haiyan Yang
- E-Mail: 2054451461@qq.com
-
Hangzhou, China
- Rekrutierung
- The First Affiliated Hospital, Zhejiang University
-
Hauptermittler:
- Zhen Cai
-
Kontakt:
- Zhen Cai
- Telefonnummer: 13857190311
- E-Mail: czclinicaltrial@163.com
-
Harbin, China
- Rekrutierung
- Harbin Medical University Cancer Hospital
-
Kontakt:
- Qingyuan Zhang
- Telefonnummer: 13313612989
- E-Mail: sy86298276@163.com
-
Hauptermittler:
- Qingyuan Zhang
-
Hefei, China
- Rekrutierung
- The Second Affiliated Hospital of Anhui Medical University
-
Kontakt:
- Zhimin Zhai
- Telefonnummer: 13855147434
- E-Mail: zzzm889@163.com
-
Hauptermittler:
- Zhimin Zhai
-
Jinan, China
- Rekrutierung
- Qilu Hospital of Shandong University
-
Kontakt:
- Shuqian Xu
- Telefonnummer: 18560087013
- E-Mail: yoyoshuqian@126.com
-
Hauptermittler:
- Shuqian Xu
-
Jinan, China
- Rekrutierung
- Shandong Cancer Hospital & Institute
-
Hauptermittler:
- Zengjun Li
-
Kontakt:
- Zengjun Li
- Telefonnummer: 15735178591
- E-Mail: zengjunli@163.com
-
Kunming, China
- Noch keine Rekrutierung
- The First Affiliated Hospital of Kunming Medical University
-
Kontakt:
- Mingxia Shi
- Telefonnummer: 86 138 8806 0581
- E-Mail: shmxia2002@sina.com
-
Hauptermittler:
- Mingxia Shi
-
Nanchang, China
- Rekrutierung
- Jiangxi Cancer Hospital
-
Hauptermittler:
- Yan Huang
-
Kontakt:
- Yan Huang
- E-Mail: 29265061@qq.com
-
Nanjing, China
- Rekrutierung
- Jiangsu Cancer Hospital
-
Hauptermittler:
- Yan Zhang
-
Kontakt:
- Yan Zhang
- Telefonnummer: 13914712395
- E-Mail: zhangyan1106@njmu.edu.cn
-
Nanjing, China
- Rekrutierung
- Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
-
Kontakt:
- Jingyan Xu
- Telefonnummer: 86 13951969610
- E-Mail: xjy1967@sina.com
-
Hauptermittler:
- Jingyan Xu
-
Nanning, China
- Rekrutierung
- The First Affiliated Hospital of Guangxi Medical University
-
Hauptermittler:
- Zhigang Peng
-
Kontakt:
- Zhigang Peng
- E-Mail: 2557382235@qq.com
-
Qingdao, China
- Rekrutierung
- The Affiliated Hospital of Qingdao University
-
Kontakt:
- Xia Zhao
- Telefonnummer: 18661803088
- E-Mail: Zhaoxia@qdu.edu.cn
-
Hauptermittler:
- Xia Zhao
-
Shanghai, China
- Rekrutierung
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Hauptermittler:
- Weili Zhao
-
Kontakt:
- Weili Zhao
- Telefonnummer: 86 13512112076
- E-Mail: zwl_trial@163.com
-
Shanghai, China
- Rekrutierung
- Tongji Hospital of Tongji University
-
Kontakt:
- Ping Li
- Telefonnummer: 13564181131
- E-Mail: lilyforever76@126.com
-
Hauptermittler:
- Ping Li
-
Shanghai, China
- Noch keine Rekrutierung
- Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
-
Hauptermittler:
- Ligen Liu
-
Kontakt:
- Ligen Liu
- Telefonnummer: 86 18017337037
- E-Mail: llg3532@shtrhospital.com
-
Shenyang, China
- Rekrutierung
- Shengjing Hospital of China Medical University
-
Hauptermittler:
- Wei Yang
-
Kontakt:
- Wei Yang
- Telefonnummer: 18940251012
- E-Mail: sjyangw@163.com
-
Shenzhen, China
- Rekrutierung
- Shenzhen people's hospital
-
Hauptermittler:
- Jihao Zhou
-
Kontakt:
- Jihao Zhou
- Telefonnummer: 86 18718678693
- E-Mail: zhoujihao@aliyun.com
-
Taiyuan, China
- Rekrutierung
- Shanxi Provincial Cancer Hospital
-
Hauptermittler:
- Liping Su
-
Kontakt:
- Liping Su
- Telefonnummer: 13835158122
- E-Mail: slpsy2022@163.com
-
Tangshan, China
- Rekrutierung
- North China University of Science and Technology Affiliated Hospital
-
Kontakt:
- Zhenyu Yan
- Telefonnummer: 15931508262
- E-Mail: hbyzy2011@163.com
-
Hauptermittler:
- Zhenyu Yan
-
Tianjin, China
- Rekrutierung
- Tianjin Medical University Cancer Institute & Hospital
-
Hauptermittler:
- Zhengzi Qian
-
Kontakt:
- Zhengzi Qian
- Telefonnummer: 13702031222
- E-Mail: qzz@163.com
-
Tianjin, China
- Rekrutierung
- Tianjin People's Hospital
-
Kontakt:
- Xingli Zhao
- Telefonnummer: 13752255454
- E-Mail: insectzhao@163.com
-
Hauptermittler:
- Xingli Zhao
-
Tianjin, China
- Rekrutierung
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
Hauptermittler:
- Dehui Zou
-
Kontakt:
- Dehui Zou
- Telefonnummer: 13602100955
- E-Mail: zoudehui@ihcams.ac.cn
-
Wenzhou, China
- Rekrutierung
- The First Affiliated Hospital of WMU
-
Kontakt:
- Songfu Jiang
- Telefonnummer: 86 15305770033
- E-Mail: jiangsongfu@189.cn
-
Hauptermittler:
- Songfu Jiang
-
Wuhan, China
- Rekrutierung
- Hubei Cancer Hospital
-
Hauptermittler:
- Huijing Wu
-
Kontakt:
- Huijing Wu
- E-Mail: 3269614878@qq.com
-
Wuhan, China
- Rekrutierung
- Wuhan Union Hospital of China
-
Hauptermittler:
- Liling Zhang
-
Kontakt:
- Liling Zhang
- Telefonnummer: 15871725926
- E-Mail: lily1228@sina.com
-
Xi'an, China
- Rekrutierung
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Hauptermittler:
- Pengcheng He
-
Kontakt:
- Pengcheng He
- Telefonnummer: 18991232609
- E-Mail: hepc_gcp@163.com
-
Xi'an, China
- Rekrutierung
- The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
-
Hauptermittler:
- Jie Liu
-
Kontakt:
- Jie Liu
- Telefonnummer: 86 18092662371
- E-Mail: lieujie@163.com
-
Xiamen, China
- Noch keine Rekrutierung
- The First Affiliated Hospital of Xiamen University
-
Hauptermittler:
- Bing Xu
-
Kontakt:
- Bing Xu
- Telefonnummer: 86 18750918842
- E-Mail: xubingzhangjian@126.com
-
Xuzhou, China
- Rekrutierung
- The Affiliated Hospital of Xuzhou Medical University
-
Kontakt:
- Wei Sang
- Telefonnummer: 86 13645207648
- E-Mail: 13645207648@126.com
-
Hauptermittler:
- Wei Sang
-
Zhengzhou, China
- Rekrutierung
- Henan Cancer Hospital
-
Hauptermittler:
- Keshu Zhou
-
Kontakt:
- Keshu Zhou
- Telefonnummer: 13674902391
- E-Mail: dr_zkshu23810@163.com
-
Zhengzhou, China
- Rekrutierung
- The First Affiliated Hospital of Zhengzhou University
-
Kontakt:
- Xudong Zhang
- Telefonnummer: 13633825183
- E-Mail: feverxxd@126.com
-
Hauptermittler:
- Xudong Zhang
-
Ürümqi, China
- Rekrutierung
- People's Hospital of Xinjiang Uygur Autonomous Region
-
Hauptermittler:
- Yan Li
-
Kontakt:
- Yan Li
- Telefonnummer: 86 13639935315
- E-Mail: liyan232917@139.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Rekrutierung
- Fudan University Shanghai Cancer Center
-
Kontakt:
- Fangfang Lv
- Telefonnummer: 18017312613
- E-Mail: Lvff80@163.com
-
Hauptermittler:
- Fangfang Lv
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Sign the ICF and be able to follow the requirements of study protocol;
- Age ≥18 years;
- ECOG performance status score between 0 and 2;
- Histopathologically confirmed diagnosis of DLBCL;
- The investigator judges that the patient's current condition requires further treatment;
- Patients should have at least one bi-dimensionally measurable lesion;
- Expected survival is more than 12 weeks;
Exclusion Criteria:
- Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
- Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
- Organ insufficiency;
- Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
- Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
- The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
- Clinically significant active infection;
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: The experimental group
Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
Patients will receive HMPL-760 once daily (QD) orally. R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Andere Namen:
|
|
Placebo-Komparator: The control group
Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group. |
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Andere Namen:
Patients will receive HMPL-760 placebo once daily (QD) orally. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free survival (PFS)
Zeitfenster: Up to approximately two years
|
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first. |
Up to approximately two years
|
|
End of treatment (EOT)
Zeitfenster: Up to approximately two years
|
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy). |
Up to approximately two years
|
|
Systemic antitumor therapy
Zeitfenster: Up to approximately two years
|
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy). |
Up to approximately two years
|
|
Overall survival (OS)
Zeitfenster: Up to approximately two years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately two years
|
|
systematic anti-tumor therapy
Zeitfenster: Up to approximately two years
|
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
|
Premature withdrawal from study treatment
Zeitfenster: Up to approximately two years
|
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Independent review committee (IRC)-assessed PFS
Zeitfenster: Up to approximately two years
|
Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). |
Up to approximately two years
|
|
IRC- and investigator-assessed objective response rate (ORR)
Zeitfenster: Up to approximately two years
|
Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) |
Up to approximately two years
|
|
IRC- and investigator-assessed complete response rate (CRR)
Zeitfenster: Up to approximately two years
|
Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR) |
Up to approximately two years
|
|
IRC- and investigator-assessed duration of response (DoR)
Zeitfenster: Up to approximately two years
|
For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first |
Up to approximately two years
|
|
IRC- and investigator-assessed clinical benefit rate (CBR)
Zeitfenster: Up to approximately two years
|
Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD) |
Up to approximately two years
|
|
IRC- and investigator-assessed time to response (TTR)
Zeitfenster: Up to approximately two years
|
Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) |
Up to approximately two years
|
|
Safety Endpoints
Zeitfenster: Up to approximately two years
|
|
Up to approximately two years
|
|
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Zeitfenster: At the end of Cycle 4 (each cycle is 21 days)]
|
including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. |
At the end of Cycle 4 (each cycle is 21 days)]
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Biomarker assessment
Zeitfenster: Up to approximately two years
|
Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy. |
Up to approximately two years
|
|
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Zeitfenster: Up to approximately two years
|
Human metabolites of HMPL-760 when co-administered with R-GemOx |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years
|
maximum concentration in steady-state (Cmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years
|
time to maximum concentration in steady-state (Tmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years
|
Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years
|
The rate at which the drug is eliminated from the body (CL/F) (if applicable ) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years
|
The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable) |
Up to approximately two years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Weili Zhao, Ruijin Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom, Non-Hodgkin
- Lymphom, B-Zell
- Lymphom
- Hämische und lymphatische Krankheiten
- Lymphom, große B-Zelle, diffus
- Aminosäuren, Peptide und Proteine
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Therapeutika
- Routen der Arzneimittelverwaltung
- Arzneimitteltherapie
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Koordinationskomplexe
- Desoxycytidin
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Antikörper, monoklonale, murine abgeleitete
- Oxaliplatin
- Rituximab
- Gemcitabin
- Injektionen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2025-760-00CH1
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .